|
1
|
Crump M, Neelapu SS, Farooq U, Van Den
Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L,
et al: Outcomes in refractory diffuse large B-cell lymphoma:
Results from the international SCHOLAR-1 study. Blood.
130:1800–1808. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Locke FL, Ghobadi A, Jacobson CA, Miklos
DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT,
Timmerman JM, et al: Long-term safety and activity of axicabtagene
ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A
single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 20:31–42.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abramson JS, Palomba ML, Gordon LI,
Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG,
Andreadis C, et al: Lisocabtagene maraleucel for patients with
relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001):
A multicentre seamless design study. Lancet. 396:839–852. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ying Z, Yang H, Guo Y, Li W, Zou D, Zhou
D, Wang Z, Zhang M, Wu J, Liu H, et al: Long-term outcomes of
relmacabtagene autoleucel in Chinese patients with
relapsed/refractory large B-cell lymphoma: Updated results of the
RELIANCE study. Cytotherapy. 25:521–529. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Neelapu SS, Jacobson CA, Ghobadi A, Miklos
DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT,
Timmerman JM, et al: Five-year follow-up of ZUMA-1 supports the
curative potential of axicabtagene ciloleucel in refractory large
B-cell lymphoma. Blood. 141:2307–2315. 2023.PubMed/NCBI
|
|
6
|
Lee DW, Gardner R, Porter DL, Louis CU,
Ahmed N, Jensen M, Grupp SA and Mackall CL: Current concepts in the
diagnosis and management of cytokine release syndrome. Blood.
124:188–195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Topp MS, van Meerten T, Houot R, Minnema
MC, Bouabdallah K, Lugtenburg PJ, Thieblemont C, Wermke M, Song KW,
Avivi I, et al: Earlier corticosteroid use for adverse event
management in patients receiving axicabtagene ciloleucel for large
B-cell lymphoma. Br J Haematol. 195:388–398. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li P, Liu Y, Liang Y, Bo J, Gao S, Hu Y,
Hu Y, Huang H, Huang X, Jing H, et al: 2022 Chinese expert
consensus and guidelines on clinical management of toxicity in
anti-CD19 chimeric antigen receptor T-cell therapy for B-cell
non-Hodgkin lymphoma. Cancer Biol Med. 20:129–146. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hughes AD, Teachey DT and Diorio C: Riding
the storm: Managing cytokine-related toxicities in CAR-T cell
therapy. Semin Immunopathol. 46:52024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McNerney KO, DiNofia AM, Teachey DT, Grupp
SA and Maude SL: Potential Role of IFNγ inhibition in refractory
cytokine release syndrome associated with CAR T-cell therapy. Blood
Cancer Discov. 3:90–94. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Strati P, Ahmed S, Furqan F, Fayad LE, Lee
HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, et al:
Prognostic impact of corticosteroids on efficacy of chimeric
antigen receptor T-cell therapy in large B-cell lymphoma. Blood.
137:3272–3276. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Davila ML, Riviere I, Wang X, Bartido S,
Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska
M, et al: Efficacy and toxicity management of 19-28z CAR T cell
therapy in B cell acute lymphoblastic leukemia. Sci Transl Med.
6:224ra2252014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rainone M, Ngo D, Baird JH, Budde LE, Htut
M, Aldoss I and Pullarkat V: Interferon-γ blockade in CAR T-cell
therapy-associated macrophage activation syndrome/hemophagocytic
lymphohistiocytosis. Blood Adv. 7:533–536. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sehn LH and Salles G: Diffuse large B-cell
lymphoma. N Engl J Med. 384:842–858. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Meignan M, Gallamini A, Meignan M,
Gallamini A and Haioun C: Report on the first international
workshop on interim-PET-scan in lymphoma. Leuk Lymphoma.
50:1257–1260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Neelapu SS, Locke FL, Bartlett NL, Lekakis
LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T,
Lin Y, et al: Axicabtagene ciloleucel CAR T-cell therapy in
refractory large B-cell lymphoma. N Engl J Med. 377:2531–2544.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ying Z, Yang H, Guo Y, Li W, Zou D, Zhou
D, Wang Z, Zhang M, Wu J, Liu H, et al: Relmacabtagene autoleucel
(relma-cel) CD19 CAR-T therapy for adults with heavily pretreated
relapsed/refractory large B-cell lymphoma in China. Cancer Med.
10:999–1011. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hayden PJ, Roddie C, Bader P, Basak GW,
Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R,
et al: Management of adults and children receiving CAR T-cell
therapy: 2021 Best practice recommendations of the European society
for blood and marrow transplantation (EBMT) and the Joint
accreditation committee of ISCT and EBMT (JACIE) and the European
haematology association (EHA). Ann Oncol. 33:259–275. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Manni S, Del Bufalo F, Merli P, Silvestris
DA, Guercio M, Caruso S, Reddel S, Iaffaldano L, Pezzella M, Di
Cecca S, et al: Neutralizing IFNγ improves safety without
compromising efficacy of CAR-T cell therapy in B-cell malignancies.
Nat Commun. 14:34232023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Carbone A, Roulland S, Gloghini A, Younes
A, von Keudell G, López-Guillermo A and Fitzgibbon J: Follicular
lymphoma. Nat Rev Dis Primers. 5:832019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schmitz R, Wright GW, Huang DW, Johnson
CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer
AL, et al: Genetics and pathogenesis of diffuse large B-cell
lymphoma. N Engl J Med. 378:1396–1407. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Norelli M, Camisa B, Barbiera G, Falcone
L, Purevdorj A, Genua M, Sanvito F, Ponzoni M, Doglioni C,
Cristofori P, et al: Monocyte-derived IL-1 and IL-6 are
differentially required for cytokine-release syndrome and
neurotoxicity due to CAR T cells. Nat Med. 24:739–748. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Maude SL, Barrett D, Teachey DT and Grupp
SA: Managing cytokine release syndrome associated with novel T
cell-engaging therapies. Cancer J. 20:119–122. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kotch C, Barrett D and Teachey DT:
Tocilizumab for the treatment of chimeric antigen receptor T
cell-induced cytokine release syndrome. Expert Rev Clin Immunol.
15:813–822. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee DW, Kochenderfer JN, Stetler-Stevenson
M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M,
Shah NN, et al: T cells expressing CD19 chimeric antigen receptors
for acute lymphoblastic leukaemia in children and young adults: A
phase 1 dose-escalation trial. Lancet. 385:517–528. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang H, Lv X, Kong Q and Tan Y:
IL-6/IFN-γ double knockdown CAR-T cells reduce the release of
multiple cytokines from PBMCs in vitro. Hum Vaccin Immunother.
18:1–14. 2022. View Article : Google Scholar
|
|
27
|
Bailey SR, Vatsa S, Larson RC, Bouffard
AA, Scarfò I, Kann MC, Berger TR, Leick MB, Wehrli M, Schmidts A,
et al: Blockade or deletion of IFNγ reduces macrophage activation
without compromising CAR T-cell Function in hematologic
malignancies. Blood Cancer Discov. 3:136–153. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Locatelli F, Jordan MB, Allen C, Cesaro S,
Rizzari C, Rao A, Degar B, Garrington TP, Sevilla J, Putti MC, et
al: Emapalumab in children with primary hemophagocytic
lymphohistiocytosis. N Engl J Med. 382:1811–1822. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schuelke MR, Bassiri H, Behrens EM, Canna
S, Croy C, DiNofia A, Gollomp K, Grupp S, Lambert M, Lambrix A, et
al: Emapalumab for the treatment of refractory cytokine release
syndrome in pediatric patients. Blood Adv. 7:5603–5607. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Teachey DT, Lacey SF, Shaw PA, Melenhorst
JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein
J, et al: Identification of predictive biomarkers for cytokine
release syndrome after chimeric antigen receptor T-cell therapy for
acute lymphoblastic leukemia. Cancer Discov. 6:664–679. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Al-Salama ZT: Emapalumab: First global
approval. Drugs. 79:99–103. 2019. View Article : Google Scholar : PubMed/NCBI
|
